GT BIOPHARMA INC (GTBP) Stock Price, Quote, News and Overview
NASDAQ:GTBP - Nasdaq - US36254L3087 - Common Stock - Currency: USD
GTBP Quote, Performance and Key Statistics
NASDAQ:GTBP (3/7/2025, 8:00:01 PM)
2.44
+0.07 (+2.95%)
The current stock price of GTBP is 2.44 USD. In the past month the price increased by 11.42%. In the past year, price decreased by -43.52%.
GTBP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About GTBP
Company Profile
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 2 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The firm is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
Company Info
GT BIOPHARMA INC
315 Montgomery Street, 10Th Floor
San Francisco CALIFORNIA 90212 US
CEO: Anthony J. Cataldo
Employees: 2
Company Website: https://www.gtbiopharma.com/
Phone: 18003049888
GT BIOPHARMA INC / GTBP FAQ
What is the stock price of GT BIOPHARMA INC today?
The current stock price of GTBP is 2.44 USD. The price increased by 2.95% in the last trading session.
What is the ticker symbol for GT BIOPHARMA INC stock?
The exchange symbol of GT BIOPHARMA INC is GTBP and it is listed on the Nasdaq exchange.
On which exchange is GTBP stock listed?
GTBP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GT BIOPHARMA INC stock?
7 analysts have analysed GTBP and the average price target is 11.22 USD. This implies a price increase of 359.84% is expected in the next year compared to the current price of 2.44. Check the GT BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GT BIOPHARMA INC worth?
GT BIOPHARMA INC (GTBP) has a market capitalization of 5.44M USD. This makes GTBP a Nano Cap stock.
How many employees does GT BIOPHARMA INC have?
GT BIOPHARMA INC (GTBP) currently has 2 employees.
What are the support and resistance levels for GT BIOPHARMA INC (GTBP) stock?
GT BIOPHARMA INC (GTBP) has a support level at 2.42 and a resistance level at 2.45. Check the full technical report for a detailed analysis of GTBP support and resistance levels.
Should I buy GT BIOPHARMA INC (GTBP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GTBP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GTBP, evaluating the profitability, health, valuation and growth aspects
- GT BIOPHARMA INC (GTBP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GT BIOPHARMA INC (GTBP) Sales and EPS estimates to see what analysts future expectations are.
- GT BIOPHARMA INC (GTBP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GT BIOPHARMA INC (GTBP) Insider and Institutional Ownership to learn about the owners and their transactions.
- GT BIOPHARMA INC (GTBP) Stock Chart to make your own analysis
- GT BIOPHARMA INC (GTBP) Latest news and press-releases to stay up to date.
Does GT BIOPHARMA INC (GTBP) stock pay dividends?
GTBP does not pay a dividend.
When does GT BIOPHARMA INC (GTBP) report earnings?
GT BIOPHARMA INC (GTBP) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of GT BIOPHARMA INC (GTBP)?
GT BIOPHARMA INC (GTBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.79).
What is the Short Interest ratio of GT BIOPHARMA INC (GTBP) stock?
The outstanding short interest for GT BIOPHARMA INC (GTBP) is 9.6% of its float. Check the ownership tab for more information on the GTBP short interest.
GTBP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GTBP. When comparing the yearly performance of all stocks, GTBP is a bad performer in the overall market: 84.16% of all stocks are doing better.
GTBP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GTBP. GTBP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GTBP Financial Highlights
Over the last trailing twelve months GTBP reported a non-GAAP Earnings per Share(EPS) of -5.79. The EPS increased by 71.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -182.7% | ||
| ROE | -588.89% | ||
| Debt/Equity | 0 |
GTBP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GTBP. The Buy consensus is the average rating of analysts ratings from 7 analysts.